AUTL Stock Analysis: Buy, Sell, or Hold?
AUTL - Autolus Therapeutics plc American Depositary Share
$2.22
0.10 (4.72%)
▲
5d:
+11.0%
30d:
+47.02%
90d:
+29.82%
WAIT
LOW Confidence
Analysis Updated: Aug 13, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When AUTL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: AUTL is 13.3% above its trading range ($1.96). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: AUTL is 13.3% above its trading range ($1.96). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: AUTL is currently trading at $2.22, which is considered extended relative to its 30-day fair value range of $1.41 to $1.96.
Technical Outlook: Technically, AUTL is in a uptrend. Immediate support is located at $1.47, while resistance sits at $2.43. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: AUTL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.68 (+290.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AUTL is in a uptrend. Immediate support is located at $1.47, while resistance sits at $2.43. The stock is showing strong short-term momentum, up 4.7% recently.
Market Sentiment: AUTL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $8.68 (+290.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.41 -
$1.96
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price significantly overextended (+13.3% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.7%)
- BULLISH: Trading 290.8% below Wall St target ($8.68)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.41 -
$1.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.47
Resistance Level
$2.43
Current Trend
Uptrend
Technical data as of
Aug 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.75
Wall Street Target
$8.68
(+290.8%)
Revenue Growth (YoY)
83655.2%
Share & Embed Analysis
Last updated: August 13, 2026 9:53 PM ET
Data refreshes hourly during market hours. Next update: 10:53 PM
Data refreshes hourly during market hours. Next update: 10:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AUTL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 52 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 49 HOLD |
